Progresif Maküler Hipomelanozis

Abstract

Progresif maküler hipomelanozis (PMH) ilk olarak 1988 y›l›nda Guillet taraf›ndan tan›mlanm›flt›r. PMH s›kl›kla gövdeyi tutan, asemptomatik, zor fark edilen, numuler, skuams›z, hipopigmente maküllerle karakterizedir. PMH ço¤unlukla adölesan ve genç kad›nlarda görülür. Etyopatogenezi hala bilinmemektedir. Wood lambas› alt›nda hipopigmente maküllerde k›rm›z› foliküler florasan görünürken komflu normal deride florasan gözlenmez. PMH'nin histopatolojik bulgular› genellikle non-spesifiktir, ancak hipopigmente maküllerin melanin içeri¤inin normal deriye göre azalm›fl olmas› s›k görülen bir bulgudur. Etkili bir tedavi halen bilinmemektedir. Ancak fototerapi PMH'yi kontrol alt›na almada etkili bulunmufl olmas›na karfl›n hastal›¤›n rekürrensini önlememektedir. Biz bu makalede PMH'nin etyopatogenezi, klinik bulgular›, histopatolojisi, ay›r›c› tan›s› ve tedavi seçeneklerini derlemeyi amaçlad›k. (Türkderm 2011; 45: 62-5) Anahtar Kelimeler: Progresif maküler hipomelanozis, pigmentasyon bozukluklar› SummaryProgressive macular hypomelanosis (PMH) was initially described and named by Guillet in 1988. PMH is characterized by asymptomatic, ill-defined, nummular, non-scaly, hypopigmented macules, localized predominantly on the trunk. PMH is mostly seen in adolescents and young females. The etiopathogenesis of PMH is still unknown. The red follicular fluorescence becomes visible in the hypopigmented macules under Wood's lamp but is absent in normal adjacent skin. The histopathologic findings in PMH are usually non-specific, but a common feature is the decreased melanin content in the hypopigmented macules compared to the normal skin. No effective therapy is currently known. Phototherapy was found to be effective for the control of PMH; however, it does not prevent recurrence of the disease. In this paper, we aimed to review the etiopathogenesis, clinical findings, histopathology, differential diagnosis and treatment options of PMH. (Turkderm 2011; 45: 62-5